文献速递老年慢病共病管理老年综合评估

是时候将老年人纳入炎症性肠病试验了吗?行动呼吁

Is it time to include older adults in inflammatory bowel disease trials? A call for action.
PubMed 文献 · Lancet Healthy Longev · 2022-05-04

该系统评价检索 PubMed 与 ClinicalTrials.gov 注册的 222 项炎症性肠病(IBD)3 期研究,发现 129 项(58%)以年龄作为排除标准;合并症、异型增生史和既往 IBD 治疗也是常见排除原因,作者据此提出三步流程以纳入所有老年患者。

要点

  • 222 项 IBD 3 期研究中 129 项(58%)将年龄设为排除标准。
  • 合并症(肾、肝、心血管为主)为 76% 试验的排除标准。

核心结论

  • 老年 IBD 患者因年龄被频繁排除于 3 期临床试验之外,现有证据不足以指导其治疗管理。
  • 作者提出三步流程,旨在使所有老年患者不论年龄、合并症与衰弱均可纳入 IBD 临床试验。

研究设计与样本

  • 系统评价检索 PubMed 与 ClinicalTrials.gov 注册的 IBD 3 期研究,共评估 222 项试验。
  • 提取年龄排除标准上限、≥65 岁受试者比例,并记录年龄以外排除标准,合并症单独分析。

主要发现

  • 222 项试验中 129 项(58%)将年龄作为排除标准。
  • 合并症(主要为肾、肝、心血管)为 76% 试验的排除标准,异型增生史为 45%,既往 IBD 治疗为 19%。

关键数值与推荐

  • 年龄排除标准见于 129/222 项(58%)3 期试验。
  • 合并症排除见于 76% 试验,异型增生史 45%,既往 IBD 治疗 19%。

临床怎么用

  • 老年 IBD 患者治疗决策时需认识到 3 期试验证据对 ≥65 岁人群的代表性有限。
  • 评估老年 IBD 患者入组研究时,应关注年龄、合并症与衰弱等排除标准对证据外推的影响。

局限性

  • 仅纳入 PubMed 与 ClinicalTrials.gov 注册的 3 期研究,未涵盖其他注册平台或非 3 期证据。
  • 仅 32 项试验报告 ≥65 岁受试者比例,年龄构成数据有限。
  • 原文未报告各排除标准对试验结果的具体影响及三步流程的验证数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The therapeutic management of older patients with inflammatory bowel disease (IBD) is challenging, particularly because of the absence of evidence-based guidelines for these patients, who seem to frequently be excluded from clinical trials. In this systematic review we investigated the exclusion of older patients with IBD from phase 3 studies registered on PubMed and ClinicalTrials.gov, by assessing the upper limit of age exclusion criteria and the percentage of patients older than 65 years included in the trials. Exclusion criteria other than age were also recorded, and comorbidities were analysed separately. Our review of 222 phase 3 studies shows that older patients are frequently excluded from IBD clinical trials because of their age, which was used as an exclusion criterion in 129 (58%) of the 222 assessed trials. Of the 32 trials that detailed the percentage of included patients who were 65 years or older, only 763 (5·4%) patients of the 14 124 patients included were older than 65 years. In addition to age, patients were also excluded because of comorbidities (mainly renal, hepatic, and cardiovascular, and used as an exclusion criterion in 76% of trials), a history of dysplasia (45% of trials), and previous treatment for IBD (19% of trials). We propose a three-step process that should enable the inclusion of all older patients in IBD clinical trials, regardless of their age, comorbidities, and frailty.

来源:Lancet Healthy Longev,查看原文。版权归原作者所有。

引用

  1. Vieujean S, Caron B, Jairath V, et al. Is it time to include older adults in inflammatory bowel disease trials? A call for action. Lancet Healthy Longev. 2022. PMID: 36098310. doi:10.1016/S2666-7568(22)00060-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。